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Background:  HIV/hepatitis  C  (HCV)  coinfection  is a  major  concern  in global  health  today.  Each pathogen
can  exacerbate  the effects  of  the  other  and  affect  treatment  outcomes.  Understanding  the within-host
dynamics  of these  coinfecting  pathogens  is crucial,  particularly  in  light  of new,  direct-acting  antiviral
agents  (DAAs)  for HCV  treatment  that  are  becoming  available.
Methods  and  ﬁndings:  In this  study,  we  construct  a within-host  mathematical  model  of  HCV/HIV  coin-
fection  by  adapting  a  previously  published  model  of  HCV  monoinfection  to include  an  immune  system
component  in infection  clearance.  We  explore  the  effect  of  HIV-coinfection  on  spontaneous  HCV  clearance
and sustained  virologic  response  (SVR)  by building  in  decreased  immune  function  with  increased  HIV
viral load.  Treatment  is  modeled  by modifying  HCV  burst-size,  and  we  use  clinically-relevant  parameter
estimates.
Our model  replicates  real-world  patient  outcomes;  it outputs  infected  and  uninfected  target  cell
counts,  and  HCV  viral  load  for  varying  treatment  and coinfection  scenarios.  Increased  HIV  viral  load
and  reduced  CD4+ count  correlate  with  decreased  spontaneous  clearance  and  SVR  chances.  Treatment
efﬁcacy/duration  combinations  resulting  in  SVR  are  calculated  for HIV-positive  and negative  patients,
and  crucially,  we  replicate  the  new  ﬁndings  that  highly  efﬁcacious  DAAs  reduce  treatment  differences
between  HIV-positive  and  negative  patients.  However,  we  also ﬁnd  that if  drug  efﬁcacy  decays  sufﬁciently
over  treatment  course,  SVR  differences  between  HIV-positive  and  negative  patients  reappear.
Conclusions:  Our  model  shows  theoretical  evidence  of  the  differing  outcomes  of HCV  infection  in  cases
where  the  immune  system  is compromised  by HIV.  Understanding  what controls  these  outcomes  is
especially  important  with  the  advent  of  efﬁcacious  but often  prohibitively  expensive  DAAs.  Using  a  model
to predict  patient  response  can lend  insight  into  optimal  treatment  design,  both  in  helping  to  identify
patients  who  might  respond  well  to treatment  and  in  helping  to identify  treatment  pathways  and  pitfalls.
©  2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction and background
HIV–HCV coinfection is a whole greater than the sum of its parts,
ue to the potentiating effect each virus can have on the other. It
s an increasing concern in certain populations including people
ho inject drugs (PWID) and men  who have sex with men  (MSM).
nderstanding the within-host dynamics of coinfection is crucial
or designing treatment strategies that will avoid complications
uch as hepatotoxicity and treatment failure, while minimizing the
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/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
cost of treatment. There is a rich literature on monoinfection with
each pathogen (e.g. Ho et al., 1995; Neumann et al., 1998; Perelson,
1999; Dixit et al., 2004; Perelson et al., 2005; Biafore and D’Attellis,
2006; Reluga et al., 2009; Debroy et al., 2011) but to the best of
our knowledge, within-host HIV–HCV coinfection has not yet been
modeled.
HIV and HCV are both viral infections that can be blood-borne.
They are often transmitted together, especially among PWID (Alter,
2006; Vickerman et al., 2013). The infections can interact synergis-
tically: broadly, HIV causes deterioration of the immune system,
which can lead to poorer control and clearance rates of HCV as
well as reduced probability of treatment success (Kim and Chung,
2009), while HCV may  increase progression rates of HIV through
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Cig. 1. Within-host HIV–HCV interactions. Dashed black arrows represent mecha
opulation-biological effects taken into account in our model. (For interpretation o
he  article.)
hronic immune activation or increased CD4 apoptosis (Gonzalez
t al., 2010). Treatment success for HCV is deﬁned as achieving
ustained virologic response (SVR), i.e. HCV RNA is undetectable
uring treatment and for 6 months beyond treatment end (Feld
nd Hoofnagle, 2005).
We  approach clinical implications of coinfection with a
ynamic-static mathematical model, based on a previously pub-
ished dynamical model of HCV monoinfection (Dahari et al., 2005;
eluga et al., 2009; Debroy et al., 2011) to include an explicit ele-
ent of immune control. We  then perturb the system by adding
IV infection as a static parameter, which erodes immune control
nd thus changes the HCV dynamics. Lastly, we explore how this
oss of control impacts HCV treatment outcomes.
Understanding phenomena that may  impact treatment out-
omes is especially important with the advent of new direct-acting
ntiviral agents (DAAs) such as Sofosbuvir that are becoming avail-
ble for HCV treatment. These new drugs are highly efﬁcacious, but
till very expensive, so thoughtful treatment design and adminis-
ration is necessary (NatMed, 2014; Guedj et al., 2010; Ahlén et al.,
013).
.1. Immune/HCV interactions
The immune response to HCV is complex and involves both
nnate and adaptive components. The adaptive response to HCV is
ostly T-cell dependent. Virus-speciﬁc CD4+ and CD8+ responses
ave been detected during acute infection, and it is thought
hat these cells may  clear virus by lysing infected cells or by
ytokine/chemokine-mediated effects (Kim and Chung, 2009).
HCV may  be responsible for immune dysregulation itself; some
tudies indicate an inverse correlation between HCV viral load and
D4+ count (Mohsen et al., 2002). HCV may  also downregulate of HIV–HCV interaction described in the literature. Solid blue arrows represent
eferences to color in this ﬁgure legend, the reader is referred to the web version of
proliferation of T cells or increase apoptosis. Increased immune
activation in coinfected versus monoinfected patients has been
noted, which also may  speed HIV progression (Gonzalez et al.,
2009). A schematic summary of HIV–HCV interaction effects is
shown in Fig. 1.
1.1.1. Empirical evidence for effect of HIV infection on HCV
clearance and treatment response
Patients who  are able to clear HCV spontaneously have been
noted to mount intense multispeciﬁc CD4+ and CD8+ responses,
in particular with HCV-speciﬁc CD4+ Th1 responses (Roe and
Hall, 2008). Complementarily, some studies show that lower CD4+
counts are associated with reduced probability of clearing (Kim and
Chung, 2009). However, HCV can avoid these responses through
mutation and inhibition of dendritic cell activation and produc-
tion of Th1 cytokines. This can prevent cytotoxic lymphocyte
(CTL)-induced apoptosis of infected hepatocytes, which can in turn
increase viral production (Roe and Hall, 2008).
Some HIV-positive patients do clear HCV, but in much lower pro-
portions than HIV-negative individuals. The correlative evidence
for mechanism is mixed. Higher rates of chronic HCV are inversely
correlated with CD4+ count according to some studies reviewed by
Kim and Chung (2009). A study in chimpanzees showed reduced
endurance of HCV-speciﬁc CD8+ CTL response after depletion of
CD4+ cells before reinfection; viremia upon reinfection was persis-
tent despite the presence of functional CD8+ T-cells (Grakoui et al.,
2003). Other studies have found more general negative correla-
tion between HIV viral load and SVR (Thomas, 2006; Roe and Hall,
2008). The phenomenon of increased persistence of HCV among
HIV-positive patients is related to and accompanied by an increased
HCV viral load.
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A number of empirical studies show elevated HCV viral load
0.1–1 logs higher) among HIV-positive as compared to HIV-
egative patients (Di Martino et al., 2001; Danta et al., 2008;
ohsen et al., 2002; Roe and Hall, 2008). The cause is most likely
educed immune response: coinfection is associated with lack of
ritical CD4+ response to HCV (Danta et al., 2008; Harcourt et al.,
006). Indeed, the study in chimpanzees mentioned above showed
hat CD8+ T-cells had impaired control of viral replication with
nsufﬁcient CD4+ help (Grakoui et al., 2003), and there is evidence
hat broad CD4+ responses play a major role in HCV clearance
Diepolder et al., 1995).
.1.2. Role of HIV treatment
In clinical settings where HCV treatment is available, most
oinfected patients will have been treated with anti-retroviral ther-
py (ART) for HIV prior to receiving treatment for HCV despite
ome risks of hepatotoxicity from ART (Soriano et al., 2007; Taylor
t al., 2012). However, even when ART is successful and results
n achievement of virological suppression, CD4+ recovery is often
ncomplete. Many studies have shown that CD4+ count at simi-
ar durations after ART initiation varies widely, and is correlated
ith a range of patient characteristics such as nadir CD4+ count
Kaufmann et al., 2003; McKinnon et al., 2010; Takuva et al., 2014)
see Supplementary Fig. 1). Correspondingly, there is evidence that
ven coinfected patients who are treated for HIV have a lower prob-
bility of clearing HCV (Schnuriger et al., 2009) or achieving SVR
Laguno et al., 2004; Dore et al., 2007; Andreoni et al., 2012).
.2. Previous models of HCV
Some of the ﬁrst within-host models of HCV aimed to cap-
ure the dynamics of infection by pairing a mathematical model
ith patient data from a trial of varying doses of interferon (IFN)
reatment (Neumann et al., 1998; Perelson, 1999). The viral load
atterns upon treatment observed (i.e. rapid initial decline in viral
oad followed by extended slow decline) were consistent with the
ain mechanism of IFN treatment being reduction in production
f new virus by infected cells (burst size). Higher doses were more
ffective, and lower diversity of quasi-species were associated with
etter response to treatment.
Extensions to this model take into account complexities sur-
ounding treatment response, such as non-response, rebound in
iral load (relapse), or treatment with other therapies (Perelson
t al., 2005; Dixit et al., 2004).
.2.1. Models of extended infection
The aforementioned models deal with acute HCV infection and
reatment dynamics over the course of several days or weeks. HCV
an be a long course infection, however, and models can capture
onger term dynamics as well.
The model created for this study is based on previous works
Reluga et al., 2009; Debroy et al., 2011; Dahari et al., 2005) and
xplores treatment dynamics past initial infection in detail. The
onditions for achievement of SVR can be inconsistent. For exam-
le, the “End-of-Treatment” response, deﬁned as undetectable viral
oad (below 2 logs) at the end of a 24 or 48 week course of treatment,
s necessary but not sufﬁcient for SVR. Debroy et al. (2011) analyze
edium- and long-term responses leading to either a viral endemic
quilibrium or a disease-free equilibrium to establish mathemati-
al criteria for each state. Depending on the initial conditions and
iological parameter values, there exists a possibility of bistabil-
ty for some patients (i.e. they have the capacity to clear infection,
ut only if treated adequately). The parameter values depend on
atient immunological characteristics, as well as viral characteris-
ics and interactions, which can vary by genotype (as explored bys 12 (2015) 1–10 3
Smith et al., 2010). Our model aims to extend the analysis of these
previous models in scenarios of HIV coinfection.
2. Methods
2.1. HCV monoinfection model
The model proposed in this study follows closely the above-
referenced model (Dahari et al., 2005; Reluga et al., 2009; Debroy
et al., 2011). Following a standard ODE model proposed in earlier
work (Perelson and Nelson, 1999), with some variations such as
inclusion of infected hepatocytes in density dependence, the basic
form of the equations (without the immune system component) is
as follows:
dT
dt
= s + r1T
(
1 − T + I
Tmax
)
− dT − ˇTV
dI
dt
= ˇTV + r2I
(
1 − T + I
Tmax
)
− ıI
dV
dt
= pI − cV
Here, T, I, and V are the state variables representing, respec-
tively, uninfected Target cells (hepatocytes), Infected hepatocytes,
and free HCV Virus, s is the recruitment rate for uninfected hepa-
tocytes, r1 is the reproduction rate of uninfected hepatocytes, Tmax
is the maximum number/carrying capacity of target cells, d is the
death rate of uninfected target cells,  ˇ is the mass-action infection
parameter, r2 is the reproduction rate of infected hepatocytes, ı
is the clearance rate of infected hepatocytes, p is the number of
virions an infected cell produces in its lifetime (which can also be
interpreted as burst size), and c is viral clearance rate. With this
model of HCV monoinfection as a basis, we can build a new model
of HCV that includes the role of the immune system – speciﬁcally,
CD4+ cells, denoted H in the model equations. Work by Grakoui et al.
(2003) and others has illuminated to some extent the role of CD4+
cells in HCV control, and activation of CD4+ cells by HCV has been
documented (Lechner et al., 2000; Bowen and Walker, 2005). The
model proposed here thus incorporates a dependence of the HCV
clearance rate on CD4+ count (˛) and a dependence of the activa-
tion rate of CD4+ cells on HCV infected cell count (). The equations
thus become
dT
dt
= s + r1T
(
1 − T + I
Tmax
)
− dT − ˇTV
dI
dt
= ˇTV + r2I
(
1 − T + I
Tmax
)
− ı(1 + ˛H)I
dV
dt
= pI − cV
dH
dt
= sH(1 + I)  − dHH
where sH is the recruitment rate of CD4+ cells, and dH their death
rate.
2.2. Immunological impact of HIV coinfection on HCV
Introducing HIV infection into the system will have an impact on
its dynamics. Rather than including the full complexity of within-
host HIV dynamics in this model, we have chosen to take advantage
of the differing time scales of asymptomatic HIV infection and HCV
treatment. Therefore, we  use HIV set-point viral load as a constant
4 idemic
p
s
c
H
i
v
e
w
t
a
a
p
t
a
2
c
e
(
s
e
m
s
c
2
A
a
w
m
i
w
h
c
S
t
attraction to the other (i.e. endemic equilibrium to clearance). SVR R. Birger et al. / Ep
arameter (rather than a state variable with its own dynamics)
o it contributes as a mass-action depleter of the immune system
ompartment. Perturbing the system by adding a component of
IV-infection changes the stability dynamics. To maximize simplic-
ty in the model, HIV infection was therefore modeled as a single
iral load, denoted by VH, representing the set-point viral load. The
quation for H thus becomes
dH
dt
= sH(1 + I)  − dHH − ˇHVHH
here ˇH is the mass-action infection parameter for HIV. Due to
he static nature of the incorporation of HIV into this model, we
re unable to capture dynamically the process of immune recovery
fter ART for HIV. However, as immune recovery is often incom-
lete, we can use lower values of H (we can vary sH to generate
hese values when VH≈ 0) to simulate a depleted immune system
nd thus capture the dynamics of HCV in HIV patients on ART.
.3. HCV treatment
Treatment efﬁcacy was included in the model as a parameter ε
ontrolling viral production rate as in previous work (Neumann
t al., 1998), and following Snoeck et al. (2010) and Dixit et al.
2004), we have implemented a cure boundary such that virus
tops being produced when infected cell count drops below 1. The
quations become
dT
dt
= s + r1T
(
1 − T + I
Tmax
)
− dT − ˇTV
dI
dt
= ˇTV + r2I
(
1 − T + I
Tmax
)
− ı(1 + ˛H)I
dV
dt
= (1 − ε)pI − cV
dH
dt
= sH(1 + I) − dHH − ˇHVHH
This formulation allows for implementation of imperfect treat-
ent for varying durations in this model. As explored in the next
ection, these combinations can reveal the uncertainty surrounding
ure inherent in certain patients.
.4. Bistability analysis
This model allows for cure in two types of patient systems.
s explored by Snoeck et al. (2010), including the cure bound-
ry allows the model to replicate viral dynamics in patients in
hom infection is effectively cleared (<1 infected hepatocyte in the
odeled population). These patients do not exhibit true bistability;
f infected hepatocytes are not completely cleared, the viral load
ill bounce back even from undetectable levels. In some patients,
owever, the system can by truly bistable and when infected cell
ount drops below a certain non-zero level, the patient will achieve
VR even if virus is not initially eradicated.
To explore the stability dynamics of the model, it can be useful
o make the quasi-steady state approximation. Because the virals 12 (2015) 1–10
dynamics happen on a faster time scale than the cell dynamics, we
can simplify the equations as
dT
dt
= s + r1T
(
1 − T + I
Tmax
)
− dT − (1 − ε) ˜ˇTI
dI
dt
= (1 − ε) ˜ˇTI + r2I
(
1 − T + I
Tmax
)
− ı(1 + ˛H)I
dH
dt
= sH(1 + I)  − dHH − ˇHVHH
V = p
c
I
where ˜ˇ = (p/c)ˇ.
Following Debroy et al. (2011), we calculate the within-host R0
by setting dI/dt > 0 at the start of the infection (before treatment, so
the ε term disappears), when I ≈ 0:
dI
dt
= ˜ˇTI + r2I
(
1 − T + I
Tmax
)
− ı(1 + ˛H)I > 0
˜ˇT + r2
(
1 − T
Tmax
)
> ı(1 + ˛H)
R0 =
˜ˇT0 + r2(1 − (T0/Tmax))
ı(1 + ˛H0)
> 1
where T0, H0 are the initial values of uninfected hepatocytes and
activated CD4+ cells in the absence of infection.
T0 =
Tmax
2r1
(
(r1 − d) +
√
(r1 − d)2 + 4s
r1
Tmax
)
and
H0 =
sH
dH
Bistability of a viral endemic equilibrium (EE) and a disease-free
equilibrium (DFE) can occur under certain circumstances (Debroy
et al., 2011). In this monoinfection model, bistability occurs when
the within-host R0 is close to or less than 1, and r2 > ˜ˇTmax,
r2 > ı(1 + ˛H0). There is some evidence that HCV can increase the
reproduction rate of infected cells to replace cells that were tar-
geted successfully by immune response (Roe and Hall, 2008; Kim
and Chung, 2009; Block et al., 2003; Erhardt et al., 2002; Hu et al.,
2013), so stability of an endemic equilibrium given this condition
has some clinical basis. The role of r2 in the bistability in this system
has an intuitive basis as well: the infected cell growth rate receives
contributions both from infected replication and from virion infec-
tion of healthy cells. More basically, when r2 > r1, i.e. the maximum
proliferation rate of the infected cells is greater than the maximum
proliferation rate of infected cells, the infection can invade even
at a stable, disease-free equilibrium. Interestingly, HIV-coinfection
impacts greatly the stability of the DFE, but does not impact inva-
sion probability at the stable DFE. Derivation of these conditions
can be found in Appendix A.
The stability surrounding R0 divides patients into four types:
never achieving SVR (R0 > 1), always achieving SVR (R0 < RC where
RC is the critical bifurcation value), or in the bistable region, either
experiencing spontaneous cure or experiencing viremia but with
the ability to be pushed into the clearance area by treatment. With
this formulation, it is possible to analyze numerically which val-
ues of duration and efﬁcacy can push a patient from one basin ofis thus dependent on a combination of critical efﬁcacy and time.
When the immunological impact of HIV-coinfection is included,
however, the stability dynamics change, reducing the probability
of achieving SVR (Andreoni et al., 2012).
R. Birger et al. / Epidemics 12 (2015) 1–10 5
Fig. 2. Model comparison with data. Panel a shows patient data redrawn from Snoeck et al. (2010), displaying the ﬁve types of long-term treatment outcome: SVR, null
response, partial response, breakthrough, and relapse. Panel b shows model scenarios from the model including free virus displaying these same ﬁve outcomes. Panel c shows
short-term treatment dynamics over the ﬁrst two weeks of treatment; model outputs are paired with data redrawn from Neumann et al. (1998). Panel d shows the same
scenarios as b, using a version of the model wherein the quasi-steady state assumption has been implemented, demonstrating that the long-term dynamics can be recovered.
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. Results
The model can qualitatively replicate viral dynamics observed
n HCV patients after treatment and described in previous stud-
es such as Neumann et al. (1998) and Snoeck et al. (2010). Fig. 2
emonstrates this replication, showing both the initial biphasic
ecline (model outputs paired with data redrawn from Neumann
t al., 1998 in panel c), and longer-term dynamics paired with
ata redrawn from Snoeck et al. (2010) (panels a and b). The
odel outputs shown are not explicitly ﬁtted to the data presented,
ut nonetheless replicate the viral trajectories. When the quasi-
teady state assumption is made, these longer-term dynamics can
e similarly qualitatively recovered, as seen in panel d of Fig. 2.
sing an example patient (Patient I) who exhibits true bistability
f endemic- and disease-free equilibria allows us to visualize the
mpact of HIV infection. Simulating different levels of the deple-
ion in CD4 count that might occur during the asymptomatic phase
f HIV infection shows that the zone of bistability shrinks with
ecreasing CD4+ count. The region of bistability is a region wherein
he within-host R0 is less than or close to 1 but greater than a cer-
ain critical reproductive number, RC (see Appendix for calculation
f RC). In this region, there are three distinct equilibria: the sta-
le endemic equilibrium (EE), the disease-free equilibrium (DFE)
nd a third, unstable EE. This unstable endemic equilibrium divides
iral load measures into two basins of attraction: toward the DFE
nd toward the stable EE. Fig. 3 shows how this region of bista-
ility encroaches farther into the region of spontaneous clearance
he lower the CD4+ count, and eventually erases the possibility
f spontaneous clearance for realistic values of ı. The presence of
IV depletes the immune system component (even after successful
reatment of HIV with ART) thus decreasing the probability of spon-
aneous clearance of HCV for this patient. The patient represented
as values for parameters drawn from the realistic distributions
escribed in Debroy et al. (2011) (and Supplementary Table 1). HIVparameters are adapted from Biafore and D’Attellis (2006). The set-
point viral load values tested are derived from the estimates of the
variability of HIV set-point viral load by Fraser (2007). The coin-
fection inﬂuence parameters are theoretical estimates chosen such
that model reproduces viral load levels and relationships; while
much empirical work has demonstrated qualitative relationships
indicated by these parameters (e.g. Grakoui et al., 2003; Lechner
et al., 2000; Bowen and Walker, 2005), this work does not allow for
their precise determination in this context.
The bifurcation diagram demonstrates how spontaneous clear-
ance can become non-clearance in a patient for whom the
bistability criteria hold, but using this model we can also
demonstrate differential treatment responses. Fig. 4 shows two
sample patients who  are both able to achieve SVR in a non-
immunosuppressed state. Panel a shows Patient I, the same bistable
patient as in the bifurcation diagram. Panel b shows Patient II, who
does not demonstrate true bistability, but is able to achieve SVR
with the cure boundary (i.e. when the infected hepatocyte count
drops below 1). For both patients, when HCV-mononinfected, SVR
is achievable after 24 weeks of treatment at levels of ∼80% efﬁcacy.
However, for both patients, when CD4+ is depleted partially (as in
a state where HIV viral load is controlled but CD4+ count has not
fully recovered), 24 weeks of treatment is insufﬁcient and relapse
occurs: the patient must be treated for 48 weeks to achieve SVR. In
the case when each patient is profoundly immunosuppressed (as
in untreated HIV, or no immunologic response to treatment after
very low nadir CD4+ count), SVR cannot be achieved even with 48
weeks of treatment. This time series illustrates the sensitivity of
treatment prognosis to HIV status, as well as the phenomenon that
early treatment response is necessary but not sufﬁcient to predict
whether SVR will be achieved.
However, when treatment efﬁcacy is high enough, as it can be
with the new direct-acting drugs that have recently been approved
(Jacobson et al., 2013; Lawitz et al., 2013; Keating and Vaidya,
6 R. Birger et al. / Epidemics 12 (2015) 1–10
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Fig. 3. Bifurcation diagram of stable and unstable equilibrium HCV viral loads with varying CD4+ count. This ﬁgure shows the growing bistable region and corresponding
shrinking region of spontaneous clearance for a parameter set with varying ı and within-host R0. The x-axis represents the within-host R0 in the HIV-free scenario with
the  given clearance rate parameters. The y-axis represents equilibrium HCV viral load. To the left of the bifurcation points is the zone of spontaneous clearance. If viral load
can  be pushed below the dotted lines (unstable equilibria), with sufﬁcient treatment, the patient will then be in the region of stable DFE and will be able to achieve SVR.
ı  × (1 + ˛H) ranges from d to 3 for varying CD4+ counts*. The other parameters are as follows: s = 4365, Tmax = 4.016 × 106, d = 1.06 × 10−3, ˇc = 7.3 × 10−8, p = 13.48, c = 10.06,
r1 = 2.7, r2 = 7.52, sH = 9, ˇH = 4.1 × 10−6, dH = 9 ×10−3,  ˛ = 5 ×10−3,  = 2 × 10−8. *Note: For lower CD4+ counts/higher HIV viral loads, the tips of the bifurcation trees could not
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pe  reached with clinically realistic values of ı. This fact implies that there would be
 certain point, though SVR might still be possible with sufﬁcient treatment duratio
014), HIV coinfection with incomplete CD4+ recovery no longer
ompromises SVR chances to the same extent. Sofosbuvir has been
hown to effect SVR within 12–24 weeks in both HIV-positive
nd HIV-negative HCV patients (Fernández-Montero et al., 2013;
ulkowski et al., 2014a,b; Rodriguez-Torres et al., 2015), and our
odel replicates this result for the above theoretical patients I
nd II (Fig. 6, panels a and b), (we still predict treatment fail-
re for short-duration treatment when the patients are severely
ig. 4. Effect of depleted CD4+ on infection clearance. This ﬁgure shows HCV viral load tra
nder  initial conditions of normal CD4+ count (∼1000 per L, HIV negative), and depleted 
nd  very low CD4+ count (∼10 per L, unsuppressed HIV) for treatment courses of 24 an
chieve  SVR when the patient has a normal CD4+ count is no longer sufﬁcient for either HI
reatment is extended to 48 weeks, the patients are able to achieve SVR when CD4+ coun
atient exhibiting classic bistability, while panel b shows Patient II, a theoretical patient walistic zone of spontaneous clearance for this patient when CD4 count falls below
 efﬁcacy.
immunocompromised, but most trials of Sofosbuvir in coinfected
patients have been among patients on ART with stable CD4+, e.g.
Sulkowski et al., 2014a,b; Rodriguez-Torres et al., 2015). Fig. 5
shows the pairs of treatment efﬁcacies and durations that lead to
+SVR for Patients I and II with and without depleted CD4 count from
HIV coinfection. Each point on each line represents the minimum
treatment duration necessary to achieve SVR for the corresponding
treatment efﬁcacy. In each of these scenarios, the model was run
jectories for two  sample patients with different treatment efﬁcacies and durations
CD4+ count (∼600 per L, suppressed HIV with incomplete immunologic recovery),
d 48 weeks. It can be seen that a treatment course of 24 weeks that is sufﬁcient to
V positive scenario, even when CD4+ count has partially recovered. However, when
t has partially recovered. Panel a shows these scenarios for Patient I, a theoretical
ho requires the cure boundary condition to achieve SVR.
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Fig. 5. Treatment and efﬁcacy combinations for (a) Patient I and (b) Patient II. Each point on each line denotes the minimum treatment duration necessary to achieve SVR for
the  corresponding efﬁcacy, for varying initial CD4+ counts. For any combination above a line, SVR is achieved, while for any combination below the line, SVR is not achieved.
All  scenarios were run for 96 weeks to assure that any potential relapse was captured.
Fig. 6. High-efﬁcacy treatment with short-term cure. Panels a and b demonstrate that high efﬁcacy treatment, as with DAAs, can result in SVR over a short duration (12–24
weeks)  for Patients I and II, respectively, even with incomplete CD4+ recovery (though when each patient is severely immunocompromised, short-term cure is still unlikely).
However, panels c and d show the same scenarios, but with treatment efﬁcacy declining from 95% to 70–75% efﬁcacy over the course of 12–16 weeks. When the CD4+ count
is  depleted or low (HIV-positive), the patients respond initially, but relapse after treatment efﬁcacy falls below a certain level.
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or 96 weeks (well past the maximum treatment duration tested) in
rder to capture any relapse that might occur. This ﬁgure demon-
trates how the minimum acceptable treatment efﬁcacies and
urations depend strongly on HIV status. It can be seen in this ﬁgure
hat duration/efﬁcacy pairs that will result in SVR for the patients
hen they are HIV-negative fall in the “No SVR” region when the
atient has a depleted CD4+ count. As CD4+ drops, the minimum
reatment efﬁcacy necessary for SVR increases, as does minimum
uration for a given efﬁcacy in some cases. When the patients are
everely immunocompromised, only very high efﬁcacy treatment
ill result in SVR. Lastly, as Fig. 5 suggests and Fig. 6 shows in pan-
ls c and d, in the likely event that treatment efﬁcacy declines
ver time due to non-adherence, drug resistance, or concentra-
ion decay, the differences between monoinfected and coinfected
atients may  reappear, wherein coinfected patients relapse after
reatment.
. Discussion and conclusion
In this study, we propose a model of within-host HCV infec-
ion that is able to capture broadly the impact of concurrent
reated or untreated HIV infection on clearance and long-term
ure of HCV in coinfected patients. To the best of our knowl-
dge, it is the ﬁrst within-host model of HIV–HCV coinfection; it
uilds on previous models of HCV monoinfection (Debroy et al.,
011; Reluga et al., 2009) and HIV monoinfection (Biafore and
’Attellis, 2006; Perelson and Nelson, 1999) and allows for an
xplicit role of the immune system in HCV disease course. Our
odel qualitatively replicates results of empirical research show-
ng that HIV-coinfected HCV patients have reduced probability of
pontaneous clearance of HCV as well as reduces rates of achieving
ustained virologic response (Kim and Chung, 2009; Mohsen et al.,
002; Di Martino et al., 2001). Similarly, we replicate newer empiri-
al ﬁndings indicating that highly efﬁcacious direct-acting antiviral
gents (DAAs) reduce treatment differences between HIV-positive
nd HIV-negative HCV patients (Fernández-Montero et al., 2013).
This study adds to the literature a way of capturing HCV within-
ost dynamics while accounting for the role of the immune system
nder conditions of HIV infection. It contains the ﬂexibility and
ractability necessary for testing hypotheses about clearance and
reatment. We  provide a framework which may  be useful for
ssessing a patient’s chance of responding to treatment, given
ertain virologic, immunologic and therapeutic parameters. Our
hoice to model HIV statically allows our model capture how
n immunocompromised patient can respond differently to HCV
nfection and subsequent treatment, while avoiding the problem
f parameter proliferation.
There are several limitations of the model related to the com-
lexity of the system. First, the bistability criterion that the
roliferation rate of infected cells must be greater than the pro-
iferation rate of uninfected cells only has partial support in the
iterature. Some studies report that HCV core protein can induce
roliferation in hepatocytes (Erhardt et al., 2002; Hu et al., 2013;
im and Chung, 2009; Roe and Hall, 2008) and inhibit immune-
ediate cell killing (Block et al., 2003), while others report slowed
roliferation in HCV-infected cells (Kannan et al., 2011). However,
here are may  be other mechanism of bistability, such as inter-
eron refractoriness of some cells as proposed by Padmanabhan
t al. (2014) that would yield similar impacts under the HIV coinfec-
ion conditions proposed in this model. Second, the model assumes
ery simpliﬁed within-host HIV dynamics by only including HIV
iral load as a static parameter, so may  miss some of the sub-
leties of CD4 decay and viral load changes through the course
f infection. However, this simpliﬁcation is appropriate for the
horter relative time-courses of the HCV dynamics explored here.s 12 (2015) 1–10
Similarly, while we cannot model the explicit dynamics of treat-
ment of HIV with ART, we are able to manually replicate them
by using lower equilibrium values of CD4+ count. Third, the way
we model HCV treatment does not take into account pharmacoki-
netic/pharmacodynamic complexities beyond simple, exponential
decay of treatment efﬁcacy over time, but it is useful for making
baseline calculations. It has been used in the past for modeling
interferon (IFN) treatment (Debroy et al., 2011; Reluga et al., 2009;
Perelson, 1999), but may  in fact be a better representation of the
mechanisms of DAAs (Guedj et al., 2010). IFN works by creating an
antiviral environment inside susceptible cells, thereby decreasing
their chances of getting infected (Feld and Hoofnagle, 2005), while
ribavirin can act as a mutagen and cause some proportion of viri-
ons to be non-infectious (Dixit et al., 2004). Empirical evidence
suggests that response is not directly dependent on concentra-
tion over time, but maximum drug effectiveness is correlated with
treatment response. DAAs, however, mainly work to inhibit HCV
replication thereby having a more direct effect on viral burst-size
and infectiousness (Ahlén et al., 2013).
DAAs offer very promising prognoses for HCV patients, but
are still prohibitively expensive for many (Mehta and Asch, 2014;
NatMed, 2014). It is therefore crucial to assure that the drugs
are being administered properly. Using a model to predict patient
response may  lend insight into pre-treatment estimation of treat-
ment success, and could be helpful in monitoring effectiveness of
therapy over the course of treatment. For example, if a patient
requires or takes drug holidays, a model of this type may be helpful
in predicting the maximum drug holiday allowable without com-
promising treatment. As Fig. 6 shows, HIV has the potential to alter
treatment dynamics even in optimistic scenarios, underscoring fur-
ther the importance of understanding this system.
The model results presented here give a theoretical demonstra-
tion of the effect that HIV coinfection can have on the course of
HCV infection. While the system of HCV-HIV coinfection has many
layers of complexity, we are able to use a model with relatively
simple assumptions about pathogen and immune system inter-
action to qualitatively describe patient outcomes. Not only is an
HIV-positive patient less likely to clear HCV spontaneously, but also
less likely to respond to HCV treatment when treatment efﬁcacy is
below a certain level (Kim and Chung, 2009; Mohsen et al., 2002;
Di Martino et al., 2001). Understanding what drives these treat-
ment differences can help spare difﬁcult treatment and side effects
for patients who  are unlikely to respond to treatment, as well as
informing strategies to maximize treatment adherence. HIV-HCV
coinfection is a growing issue not just among injecting drug users,
but also among HIV-positive Men  who  have sex with Men  (MSM)
who may  experience both increased transmissibility of HCV due to
higher viral load and also increased susceptibility to sexually trans-
mitted HCV due to incomplete restoration of mucosal immunity
(Kim and Chung, 2009). It is thus vital to understand the within-host
dynamics of these coinfecting pathogens in order to better assess
treatment strategies and preempt shortfall and potential resistance
acquisition.
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